These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 28741453)

  • 1. No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.
    Huang F; Ajavon A; Huang E; Lettieri J; Liu R; Peña C; Berse M
    Thyroid; 2017 Sep; 27(9):1118-1127. PubMed ID: 28741453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
    Adjei AA; Richards DA; El-Khoueiry A; Braiteh F; Becerra CH; Stephenson JJ; Hezel AF; Sherman M; Garbo L; Leffingwell DP; Iverson C; Miner JN; Shen Z; Yeh LT; Gunawan S; Wilson DM; Manhard KJ; Rajagopalan P; Krissel H; Clendeninn NJ
    Clin Cancer Res; 2016 May; 22(10):2368-76. PubMed ID: 26644411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism.
    Wang X; Zhang X; Liu F; Wang M; Qin S
    Pharm Biol; 2017 Dec; 55(1):1863-1867. PubMed ID: 28614959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
    Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
    Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
    Parvinian A; Casadaban LC; Hauck ZZ; van Breemen RB; Gaba RC
    Diagn Interv Radiol; 2015; 21(3):235-40. PubMed ID: 25835078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
    Kim A; Widemann BC; Krailo M; Jayaprakash N; Fox E; Weigel B; Blaney SM
    Pediatr Blood Cancer; 2015 Sep; 62(9):1562-6. PubMed ID: 26207356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.
    Bellesoeur A; Carton E; Mir O; Groussin L; Blanchet B; Billemont B; Clerc J; Goldwasser F
    Invest New Drugs; 2014 Jun; 32(3):569-72. PubMed ID: 24399106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
    Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.
    Mai H; Huang J; Zhang Y; Qu N; Qu H; Mei GH; Liu J; Xu X; Chen L
    Oncotarget; 2017 Jun; 8(26):43458-43469. PubMed ID: 28404979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma.
    Shimada M; Okawa H; Kondo Y; Maejima T; Kataoka Y; Hisamichi K; Maekawa M; Matsuura M; Jin Y; Mori M; Suzuki H; Shimosegawa T; Mano N
    Tohoku J Exp Med; 2015 Nov; 237(3):173-82. PubMed ID: 26477611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological evaluation of a novel sorafenib analogue, t-CUPM.
    Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily Administration of Short-Acting Liothyronine Is Associated with Significant Triiodothyronine Excursions and Fails to Alter Thyroid-Responsive Parameters.
    Jonklaas J; Burman KD
    Thyroid; 2016 Jun; 26(6):770-8. PubMed ID: 27030088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
    Widemann BC; Kim A; Fox E; Baruchel S; Adamson PC; Ingle AM; Glade Bender J; Burke M; Weigel B; Stempak D; Balis FM; Blaney SM
    Clin Cancer Res; 2012 Nov; 18(21):6011-22. PubMed ID: 22962440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
    Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
    Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study.
    Fucile C; Marenco S; Bazzica M; Zuccoli ML; Lantieri F; Robbiano L; Marini V; Di Gion P; Pieri G; Stura P; Martelli A; Savarino V; Mattioli F; Picciotto A
    Med Oncol; 2015 Jan; 32(1):335. PubMed ID: 25429830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib therapy decreases the clearance of thyrotropin.
    Verloop H; Smit JW; Dekkers OM
    Eur J Endocrinol; 2013 Feb; 168(2):163-7. PubMed ID: 23125304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
    Noda S; Shioya M; Hira D; Fujiyama Y; Morita SY; Terada T
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):269-72. PubMed ID: 23673446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination.
    Abdulrahman RM; Verloop H; Hoftijzer H; Verburg E; Hovens GC; Corssmit EP; Reiners C; Gelderblom H; Pereira AM; Kapiteijn E; Romijn JA; Visser TJ; Smit JW
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3758-62. PubMed ID: 20484486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.